Skip to Main content Skip to Navigation
Journal articles

Economic evaluations of neuraminidase inhibitors to control influenza.

Abstract : Up to 10% of individuals present influenza-like illness each year. Neuraminidase inhibitors significantly reduce the median duration of influenza symptoms by 1.38 days and median time to return to normal activities by 0.9 days in adults. This review presents the economic evaluations of neuraminidase inhibitors in adults. The choice of key parameter estimates in cost-effectiveness and cost-benefit analysis is sensitive to the perspective of analysis: healthcare payer or societal, including productivity gains. This review discusses, among other key parameters, the proportion of influenza-like illness due to the influenza virus (targeted by neuraminidase inhibitors and influenza vaccine), and the measure of health benefits by either quality-adjusted life years gained or willingness-to-pay for a day of symptoms averted. Overall, neuraminidase inhibitors are worth their costs and do not challenge annual influenza vaccination but should be seen as a complementary option to reduce the burden of influenza.
Document type :
Journal articles
Complete list of metadata

Cited literature [70 references]  Display  Hide  Download
Contributor : Michaël Schwarzinger Connect in order to contact the contributor
Submitted on : Thursday, October 27, 2011 - 12:31:04 AM
Last modification on : Sunday, June 26, 2022 - 1:18:50 AM
Long-term archiving on: : Monday, January 30, 2012 - 11:10:29 AM


Files produced by the author(s)



Michaël Schwarzinger, Karine Lacombe, Fabrice Carrat. Economic evaluations of neuraminidase inhibitors to control influenza.. Expert Review of Pharmacoeconomics and Outcomes Research, Expert Reviews, 2003, 3 (2), pp.147-58. ⟨10.1586/14737167.3.2.147⟩. ⟨inserm-00636182⟩



Record views


Files downloads